Supernus Pharmaceuticals, Inc.
NASDAQ:SUPNDrug Manufacturers - Specialty & Generic
+$0.51 today
- Market cap
- $6.02B
- Beta
- 0.54
- P/E (TTM)
- -87.6
- EPS (TTM)
- -$0.50
Volume 2.71M
Average 0.64M
SUPN Other Financing Activities
Financing cash flows not reported separately.
Supernus Pharmaceuticals, Inc.NASDAQ: SUPN
Other Financing Activities · Q2 FY2026 · quarter ended Jun 2026
Other financing activities growth accelerates
Q2 FY2026 other financing activities of $11.32M (cash outflow) rose 383.7% year over year, ahead of the -31.6% change in trailing-twelve-month other financing activities. Sequentially, it rose 148.6% from the prior quarter. Over 3 fiscal years it compounded at +7.5% a year.
Context
- Other financing activities amounted to 4.0% of revenue in FY2025, up 3.6 pp from a year earlier.
- Other financing activities grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +383.7% holds above the trailing-twelve-month pace of -31.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- (28.49M) USD
- Year-over-year change
- -949.2%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (28.49M) | -949.2% |
| FY2024 | 2024-12-31 | (2.72M) | -36.4% |
| FY2023 | 2023-12-31 | (1.99M) | +91.3% |
| FY2022 | 2022-12-31 | (22.9M) | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Financing Activities vs competitors
How SUPN compares with its peers on the latest reported figures
- SUPN's LTM Jun 2026 other financing activities of $18.58M is the smallest of the 3 companies compared; the peer median is $761.85M.
- Its year-over-year change of -31.6% is the 2nd highest of 3, against a peer median of +2333.7%.
- Other financing activities amounts to 2.2% of revenue for SUPN, versus a peer median of 44.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.5B | +4718.4% | — | 85.5% | |
| LTM Mar 2026 | $24.69M | -51.1% | — | 3.1% | |
| LTM Jun 2026 | $18.58M | -31.6% | +7.5% | 2.2% | |
| Peer median (excluding SUPN) | $761.85M | +2333.7% | — | 44.3% | |
Competitors are the stored peer set for SUPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 53.42M | 60.71M | 1.32M | 73.87M | (38.55M) |
| Depreciation & Amortization | 32.6M | 85.54M | 84.86M | 80.41M | 91.56M |
| Deferred Income Tax | (4.99M) | (26.32M) | (25.71M) | (20.14M) | 5.21M |
| Stock-Based Compensation | 17.91M | 17.57M | 26.76M | 27.76M | 33.05M |
| Change in Working Capital | 3.57M | (24.24M) | (9.14M) | (2.05M) | (75.16M) |
| Accounts Receivables | 3.87M | (16.37M) | 18.77M | 2.08M | (22.3M) |
| Inventory | (14.58M) | (17.86M) | 6.11M | 15.81M | (7.5M) |
| Accounts Payables | 18.18M | (19.16M) | (36.29M) | (15.02M) | (24.57M) |
| Other Working Capital | (3.9M) | 29.14M | 2.28M | (4.92M) | (20.79M) |
| Other Non-Cash Items | 24.62M | 3.57M | 33M | 12.11M | 31.22M |
| Operating Cash Flow | 127.13M | 116.83M | 111.09M | 171.95M | 47.33M |
| Capital Expenditures | (2.05M) | (412K) | (551K) | (725K) | (1.34M) |
| Acquisitions (Net) | (311.69M) | (14K) | 0 | 0 | (293.09M) |
| Purchases of Investments | (311.57M) | (406.99M) | (101.62M) | (688.01M) | (475.94M) |
| Sales of Investments | 530.51M | 190.74M | 370.9M | 498.86M | 774.92M |
| Other Investing Activities | 12.89M | 14K | 0 | 9K | (439K) |
| Investing Cash Flow | (81.91M) | (216.66M) | 268.73M | (189.87M) | 4.11M |
| Debt Repayment | (137.52M) | 0 | (402.5M) | 0 | 0 |
| Common Stock Issued | 7.1M | 12.42M | 6.61M | 14.91M | 37.62M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (22.9M) | (1.99M) | (2.72M) | (28.49M) |
| Financing Cash Flow | (130.42M) | (10.48M) | (397.88M) | 12.19M | 9.13M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (85.21M) | (110.31M) | (18.07M) | (5.72M) | 60.57M |
| Free Cash Flow | 125.08M | 116.41M | 110.53M | 171.23M | 45.99M |
Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
Intrinsic Alpha fair value
Locked
Current Price
$28.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.